^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SPH 3348

    i
    Other names: SPH 3348
    Associations

    News

    Trials
    Company:
    Shanghai Pharma
    Drug class:
    c-MET inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=231, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    SPH 3348
    9ms
    Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=231, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor)
    |
    SPH 3348
    1year
    Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=231, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial primary completion date: Dec 2022 --> Jun 2023
    Trial primary completion date • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor)
    |
    SPH 3348
    almost2years
    Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=231, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | N=36 --> 231 | Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Sep 2022 --> Dec 2022
    Enrollment change • Trial completion date • Trial primary completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor)
    |
    SPH 3348